FWIW I agree with JQ that the two programs at this point should be considered +/- comparable till proven otherwise. So I think the program is still viable but it'll be a harder sell for SGMO/PFE coming second to market and (not yet anyway) showing substantial differentiation.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.